drugset / Trial / NCT01179490

Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma

NCT01179490

Phase 2 Terminated 5 enrolled SymBio Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The study objectives of this study are to determine the effects, safety, and pharmacokinetics of bendamustine for multiple myeloma to a regimen of bendamustine and prednisolone.

Timeline

Start
2010-09
Primary completion
2011-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Bendamustine Small molecule 150 mg/m2 Intravenous
Background Prednisolone Other / unclassified 60 mg/m2 Oral

Indications